Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Histiocytoma, Malignant Fibrous × olaratumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 1 Liposarcoma 1 Leiomyosarcoma 1 Histiocytoma, Malignant Fibrous 1

Interventions

Doxorubicin 8 Ifosfamide 6 Radiotherapy 4 Filgrastim 2 pembrolizumab 1 pegfilgrastim 1 olaratumab 1 indolepropanol phosphate 1 brigimadlin 1 X-Rays 1 Watchful Waiting 1 Specimen Handling 1 Radiotherapy, Conformal 1 Observation 1 Gemcitabine 1 Etoposide 1 Docetaxel 1 Diathermy 1 Combined Modality Therapy 1 Chemotherapy, Adjuvant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02451943 2025-07-15

ANNOUNCE

Eli Lilly and Company

Phase 3 Completed

509 enrolled 23 charts

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon ⚡